

Rosanna Mezzapelle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3004122/publications.pdf>

Version: 2024-02-01

18
papers

1,014
citations

687363

13
h-index

839539

18
g-index

19
all docs

19
docs citations

19
times ranked

1964
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of an antagonist of HMGB1 in mice affected by malignant mesothelioma: a preliminary ultrasound and optical imaging study. <i>European Radiology Experimental</i> , 2022, 6, 7.	3.4	2
2	CXCR4/CXCL12 Activities in the Tumor Microenvironment and Implications for Tumor Immunotherapy. <i>Cancers</i> , 2022, 14, 2314.	3.7	27
3	CXCR4 engagement triggers CD47 internalization and antitumor immunization in a mouse model of mesothelioma. <i>EMBO Molecular Medicine</i> , 2021, 13, e12344.	6.9	11
4	Immunogenic cell death and immunogenic surrender: related but distinct mechanisms of immune surveillance. <i>Cell Death and Disease</i> , 2021, 12, 869.	6.3	5
5	The Chemokine Receptor CXCR4 in Cell Proliferation and Tissue Regeneration. <i>Frontiers in Immunology</i> , 2020, 11, 2109.	4.8	142
6	Diflunisal targets the <sc>HMGB</sc> 1/ <sc>CXCL</sc> 12 heterocomplex and blocks immune cell recruitment. <i>EMBO Reports</i> , 2019, 20, e47788.	4.5	34
7	Stress and Alarmins. Report from the 9th iD&EAs meeting. <i>Cell Death and Disease</i> , 2019, 10, 937.	6.3	3
8	High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair. <i>Immunological Reviews</i> , 2017, 280, 74-82.	6.0	281
9	HMGB1 as biomarker and drug target. <i>Pharmacological Research</i> , 2016, 111, 534-544.	7.1	214
10	Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells. <i>Scientific Reports</i> , 2016, 6, 22850.	3.3	36
11	Frequency of <sc>O</sc> ⁶-methylguanine-â€<sc>DNA</sc> methyltransferase promoter methylation in cytological samples from small cell lung cancer. <i>Diagnostic Cytopathology</i> , 2015, 43, 947-952.	1.0	13
12	Persistent Lung Expansion After Pleural Talc Poudrage in Non-Surgically Resected Malignant Pleural Mesothelioma. <i>Annals of Thoracic Surgery</i> , 2015, 99, 1177-1183.	1.3	19
13	Evaluation of clonal origin of malignant mesothelioma. <i>Journal of Translational Medicine</i> , 2014, 12, 301.	4.4	80
14	KRAS mutational analysis in ductal adenocarcinoma of the pancreas and its clinical significance. <i>Pathology Research and Practice</i> , 2014, 210, 307-311.	2.3	23
15	Mutation analysis of KRAS in primary colorectal cancer and matched metastases by means of highly sensitivity molecular assay. <i>Pathology Research and Practice</i> , 2013, 209, 233-236.	2.3	23
16	Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma. <i>British Journal of Cancer</i> , 2013, 108, 1743-1749.	6.4	39
17	Epidermal Growth Factor Receptor Gene Analysis With a Highly Sensitive Molecular Assay in Routine Cytologic Specimens of Lung Adenocarcinoma. <i>American Journal of Clinical Pathology</i> , 2012, 138, 377-381.	0.7	43
18	Extra-osseous Ewing sarcoma of the thyroid gland mimicking lymphoma recurrence: A case report. <i>Pathology Research and Practice</i> , 2012, 208, 356-359.	2.3	18